Prostate cancer statistics, 2025
2025/09/02 by Tyler B. Kratzer, Natalia Mazzitelli, Jessica Star +3 · 29 citations
Medicine · #Prostate Cancer Diagnosis and Treatment #Prostate Cancer Treatment and Research #Global Cancer Incidence and Screening
paper · pdf · doi:10.3322/caac.70028
Abstract
Prostate cancer is the most common cancer among men in the United States, and the incidence of advanced disease is increasing rapidly. This article provides an overview of prostate cancer occurrence using population-based incidence and mortality data from the National Cancer Institute and the Centers for Disease Control and Prevention. Prostate cancer incidence trends have reversed from a decline of 6.4% per year during 2007 through 2014 to an increase of 3.0% annually during 2014 through 2021. The increasing trend is confined to distant-stage disease in men younger than 55 years and to regional/distant-stage disease in men aged 55-69 years but includes early stage disease in men aged 70 years and older. Over the past decade of data, distant-stage disease has increased by 2.6% annually in men younger than 55 years, 6.0% annually in men aged 55-69 years, and 6.2% annually in men aged 70 years and older. American Indian/Alaska Native, Asian American/Pacific Islander, and Hispanic men are less likely than Black and White men to be diagnosed with localized disease (64%-67% vs. 71%-72%). Compared with White men, American Indian/Alaska Native men have 12% higher prostate cancer mortality despite 13% lower incidence, whereas Black men have double the prostate cancer mortality, with 67% higher incidence. In summary, continued increases in the diagnosis of advanced prostate cancer and persistent racial disparities underscore the need for redoubled efforts to optimize early detection while limiting overdiagnosis and to understand and address barriers to equitable outcomes.
Citations
Cited by
- Cancer statistics, 2026
- Exploring the biology of metastatic hormone-sensitive prostate cancer: on the road to precision medicine
- Cancer Type–Specific Contributions to the Reduction in Cancer Mortality Gap Between Black Individuals and White Individuals
- Circulating cell-free DNA profiling reveals ancestry-dependent genetic variation in metastatic prostate cancer
- Learning from prostate cancer statistics. [europepmc]
- Artificial Intelligence in Prostate MRI: Addressing Current Limitations Through Emerging Technologies. [europepmc]
- Cancer incidence, stage at diagnosis, and trends across the Navajo Nation, 2014-2018. [europepmc]
- Cancer statistics, 2026. [europepmc]
- Associations of fine particulate matter pollution components with overall, prostate cancer, and cardiovascular disease mortality in men with prostate cancer: A cohort study. [europepmc]
- Validation and context-dependent effects of a prostate cancer polygenic risk score in the All of Us Research Program. [europepmc]
- AHSP as a novel non-invasive urinary biomarker for prostate cancer. [europepmc]
- DGAT1 Drives Racially Divergent Fibroblast Activation via ERK1/2-Dependent Tumorigenic Signaling in Prostate Cancer. [europepmc]
- Early Postoperative Outcomes with the Toumai ® Surgical System for Robot-Assisted Radical Prostatectomy: A Prospective Comparative Study with da Vinci ® . [europepmc]
- In Vitro Antiproliferative Effects of Benzothiazole-Based Aminosquaraine Dyes Against Cancer Cell Lines. [europepmc]
- ADAMTS2 drives prostate cancer progression by activating FAK/PI3K/AKT signaling and suppressing ferroptosis via COL1A1. [europepmc]
- Racial and Socioeconomic Disparities in Survival Among Patients with Metastatic Prostate Cancer: A SEER Population-Based Study. [europepmc]
- Oligometastatic Prostate Cancer: Clues from an N-of-1. [europepmc]
- Olfactory Science and Technology in Prostate Cancer Diagnosis: From Invertebrate Models to Artificial Intelligence. [europepmc]
- Prioritising Data Quality Governance for AI in Prostate Cancer: A Methodological Proof-of-Concept Study Using Neural Networks for Risk Stratification. [europepmc]
- The innate immune mediator group IIA secreted phospholipase A 2 modulates lipid droplet formation in prostate cancer cells. [europepmc]
- Precision Diagnostics in Prostate Cancer Treatment (PREDICT): A Phase II Multiarm Biomarker-Based Study (Alliance A032102). [europepmc]
- Validation, implementation, and impact of an AI model in routine practice for pathologic diagnosis of prostate cancer in an academic medical center. [europepmc]
- Antibody-drug conjugates in recurrent or metastatic HNSCC: relevant targets, clinical development, and future prospects. [europepmc]
- Prostate brachytherapy followed by secondary urethral adenocarcinoma: A case report. [europepmc]
- Deciphering the role of per- and polyfluoroalkyl substances in prostate cancer: a multi-omics and computational toxicology approach. [europepmc]
- High-speed optical tracking and augmented reality platform for image-guided interventions. [europepmc]
- Emerging insights into the role of BDH1 in the pathogenesis of human cancer. [europepmc]
- Paeonol inhibits prostate cancer progression via the miR-145-5p/GOLM1 axis [europepmc]
- A Genomics-Guided Multimodal Contrastive Learning Framework for Clinically Significant Prostate Cancer Risk Stratification with Missing Clinical Data [europepmc]
Related